Menu
Home
Forums
Forums
Quick Links
Search Forums
Recent Posts
job listings
catering
whistleblower info
legal help
advertise on CP
submit press release
Menu
Log in
Sign up
Search titles only
Posted by Member:
Separate names with a comma.
Newer Than:
Search this thread only
Search this forum only
Display results as threads
More...
Useful Searches
Recent Posts
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Alexion
>
Alexion beats Q1 earnings and sales estimates; raises guidance
>
Reply to Thread
Name:
Verification:
Answer the above question:
(
CustomImgCaptcha
By
Surrey Forum
)
Message:
<p>[QUOTE="anonymous, post: 6043133"]Alexion reported a rise in Q1 2018 earnings and revenue, and lifted the guidance for the year. Along with this, the company also reported a positive top line results for its Phase 3 study.</p><p>The company that specializes in manufacturing drugs for rare disorder reported a 7% increase in its revenue to $930.9 million. Earnings per share rose 48% to $1.11 and excluding items, the company’s earnings per share rose 22% during the quarter.</p><p>Net product sales of the key drug Soliris, which accounts for a bulk of the company’s revenue and is used to treat serious genetic-based blood condition, grew 2% during the quarter to $800.1 million.</p><p><a href="https://news.alphastreet.com/alexion-beats-earnings-and-sales-estimates-raises-guidance/" target="_blank" class="externalLink ProxyLink" data-proxy-href="https://news.alphastreet.com/alexion-beats-earnings-and-sales-estimates-raises-guidance/" rel="nofollow">https://news.alphastreet.com/alexion-beats-earnings-and-sales-estimates-raises-guidance/</a>[/QUOTE]</p><p><br /></p>
[QUOTE="anonymous, post: 6043133"]Alexion reported a rise in Q1 2018 earnings and revenue, and lifted the guidance for the year. Along with this, the company also reported a positive top line results for its Phase 3 study. The company that specializes in manufacturing drugs for rare disorder reported a 7% increase in its revenue to $930.9 million. Earnings per share rose 48% to $1.11 and excluding items, the company’s earnings per share rose 22% during the quarter. Net product sales of the key drug Soliris, which accounts for a bulk of the company’s revenue and is used to treat serious genetic-based blood condition, grew 2% during the quarter to $800.1 million. [URL]https://news.alphastreet.com/alexion-beats-earnings-and-sales-estimates-raises-guidance/[/URL][/QUOTE]
Your name or email address:
Do you already have an account?
No, create an account now.
Yes, my password is:
Forgot your password?
Stay logged in
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Alexion
>
Alexion beats Q1 earnings and sales estimates; raises guidance
>
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Alexion
>
Alexion beats Q1 earnings and sales estimates; raises guidance
>